MedinCell Future Growth
Future criteria checks 5/6
MedinCell is forecast to grow earnings and revenue by 76.5% and 50.5% per annum respectively while EPS is expected to grow by 84.8% per annum.
Key information
76.5%
Earnings growth rate
84.8%
EPS growth rate
Pharmaceuticals earnings growth | 15.0% |
Revenue growth rate | 50.5% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 31 Aug 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2026 | 69 | 29 | 23 | 22 | 2 |
3/31/2025 | 33 | -11 | -6 | -6 | 4 |
3/31/2024 | 13 | -26 | -27 | -28 | 3 |
3/31/2023 | 14 | -32 | -22 | -21 | N/A |
12/31/2022 | 13 | -29 | -22 | -21 | N/A |
9/30/2022 | 8 | -27 | -22 | -20 | N/A |
6/30/2022 | 6 | -26 | -23 | -21 | N/A |
3/31/2022 | 8 | -25 | -23 | -21 | N/A |
12/31/2021 | 9 | -22 | -21 | -19 | N/A |
9/30/2021 | 9 | -20 | -18 | -17 | N/A |
6/30/2021 | 9 | -19 | -15 | -14 | N/A |
3/31/2021 | 8 | -19 | -13 | -12 | N/A |
12/31/2020 | 7 | -22 | -12 | -11 | N/A |
9/30/2020 | 5 | -26 | -11 | -10 | N/A |
6/30/2020 | 6 | -25 | -12 | -11 | N/A |
3/31/2020 | 6 | -24 | -13 | -13 | N/A |
12/31/2019 | 6 | -21 | -16 | -16 | N/A |
9/30/2019 | 6 | -19 | -19 | -19 | N/A |
6/30/2019 | 5 | -19 | -18 | -17 | N/A |
3/31/2019 | 4 | -20 | -17 | -16 | N/A |
12/31/2018 | 6 | -17 | -12 | -11 | N/A |
9/30/2018 | 7 | -15 | -8 | -7 | N/A |
6/30/2018 | 8 | -12 | -7 | -6 | N/A |
3/31/2018 | 8 | -10 | -7 | -5 | N/A |
3/31/2017 | 10 | -4 | -5 | -3 | N/A |
3/31/2016 | 9 | 1 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MEDCLP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.4%).
Earnings vs Market: MEDCLP is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MEDCLP is expected to become profitable in the next 3 years.
Revenue vs Market: MEDCLP's revenue (50.5% per year) is forecast to grow faster than the UK market (4% per year).
High Growth Revenue: MEDCLP's revenue (50.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MEDCLP's Return on Equity is forecast to be high in 3 years time